Type II Epstein-Barr virus (EBV) associated malignancies such as nasopharyngeal carcinoma and non-Hodgkin's lymphomas consistently express latent membrane 2A (LMP2A) proteins, which have been suggested to be an ideal target for immunotherapy. In previous studies we have demonstrated that using LMP2A protein loaded dendritic cells, the most powerful antigen processing cells in the body can elicit specific and robust anti-tumor cellular immune response in vitro. In this paper, we further investigated the T cell profile of the anti-tumor immune response. We found that LMP2A specific CD4 + and CD8 + T cells could be stimulated by LMP2A protein loaded dendritic cells ( 
Introduction
Tumor specific CD4 + and CD8 + T cells have been emphasized to be critical components in anti-virus and antitumor immunity (1, 2) . A successful tumor immunotherapy should include an efficient strategy to induce both CD4 + and CD8 + T cells immune responses against tumor cells (3) (4) (5) (6) . Dendritic cells are most powerful antigen-presenting cells (APCs) and capable of initiating and modulating the T cell responses including CD4 + and CD8 + T cell responses (7, 8) . Protein loaded DCs can cross-present both MHC-I class and MHC-II class epitopes to T cells and initiate CD4 + and CD8 + T cell responses (9) . It has been shown that protein-loaded DCs contain tumor specific antigens and have antigen presentating capability that makes them become a potentially attractive vector for triggering T-cell antitumor responses (11) (12) (13) (14) (15) . EBV is associated with all undifferentiated nasopharyngeal carcinoma (NPC), about 40% of Hodgkin's lymphoma, and 20-100% of non-Hodgkin's lymphomas (NHL). EBV antigens expressing in all the lymphomas restricted to EBNA1, LMP1, and LMP2 (16) (17) (18) (19) (20) . It has been shown LMP2 is the ideal tumor antigen to be chosen as target for EBV associated malignancies in immunotherapy (16, (21) (22) (23) (24) (25) . Our previous study has shown that by using purified LMP2A protein loaded Daces, strong EBV-LMP2A specific catatonic T lymphocytes (CTL) responses can be elicited (26) . However, whether these loaded Daces can elicit TH1 immune response and the subgroup of CD8 + cells which can participate in anti-tumor immune response by secreting IFN-γ and TNF- remains to be determined. In this study, we used LMP2A protein loaded Daces as Apes to stimulate T cells in vitro. We found besides a robust CTL response, LMP2A loaded Daces can also elicit specific Th1 type CD4 + T cell responses and IFN-γ secreting CTLs as well. This finding proves the concept that protein loaded DCs are potential vaccinating strategy for LMP2A positive (type II latency) EBV associated malignancies treatments.
Materials and Methods

Plasmids and cells
Retrovirus vectors pGEZ-Term, pHIT456 and pHIT60 were given by Dr. Xueguang Zhang from Soochow University. B95.8, a primate B cell line transformed by EBV, was given by Dr. Wenhan Wu in the University of Hong Kong. B lymphoblastoid cell lines (LCL) were produced by transforming healthy volunteers' peripheral blood monocytes (PBMCs) by B95.8 cell culture supernatant supplemented with cyclosporine (Sigma, USA). K562 cells were derived from chronic myelogenous leukemia cells and were obtained from The Institute of Cell Biology (Shanghai, China). Both cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Invitrogen, USA). PBMCs were separated from healthy volunteers by Ficoll gradient centrifuge. The PBMCs have been tested against HBV, HCV, HIV and syphilis.
Reagents
Cytokines IL-4, GM-CSF, TNF- and IL-2 were purchased from Peprotech, England. Heparin (12,500 U/vial) was purchased from Wan Bang Pharr. Lipofectamine 2000 and Zeocine were purchased from Invitrogen, USA. Ficoll gradient solutions were purchased from Institute of Hematology, China Academy of Medical Sciences. 3 H-TdR was purchased from The Institute of Atomic energy, China Academy of Medical Science. Rabbit anti-LMP2A antibody was kindly given by Dr. Midderdrop, Netherland. Rabbit anti-6×His-Tag antibody was purchased from ABR, USA. FITC labeled goat anti-human IgG antibody was purchased from Booster, China. The primers for amplifying and cloning LMP2A were synthesized from Bioasia, China. Pst I and EcoR I sites were added in the upstream and downstream primers respectively. The sequences: PN1, 5 '-AAC TGC  AGC ACC ATG TCT GAT AAT GGA CCC CAA TCA A-3';  PN2, 5'-GAA TTC TTA CAC CAC CAC CAC CAC CAC  TGC CTG AGT TGA ATC AGC AGA A-3' .
Blood sample
Total five peripheral blood samples from EBV positive healthy adults (male, average age 27-31) were detected for the level of anti-EBV antibodies including EBV-capsid antigen (CA) IgG, EBV-CA IgM, EBV-EA IgG, EBNA IgG by indirect immunofluorescence assay kit (EUROIMMUN, Germany), according to the instructions of EU EBVantibodies detection kit.
Immunofluorescence
In EU EBV-antibodies detection kit, biochips coated with different EVB antigens are incubated with a diluted serum sample. If the sample is positive, specific antibodies of classes IgA, IgG and IgM attach to the viral antigens. First, 25 l of different diluted serum was applied to each reaction field, and then incubated for 60 min at room temperature. The slides was rinsed for at least 5 min. Second, apply 20 l PBS Tween to fields A to D, and to field E 20 l of freshly reconstituted complement for a stronger complement reaction, then incubate for 30 min at room temperature. Rinse the slides. Third, apply 20 l of fluorescein-labelled anti-human globulin (conjugate) to each reaction field then incubate for 30 min at room temperature. Rinse the slides. Last, apply embedding medium to cover glasses. Read the fluorescence with the microscope. Induction of LMP2A specific CTL DCs were induced by IL-4 and GM-CSF cocktail as described (26) . Immature DCs (1 × 10 5 ) were loaded with 40 µg/ml LMP2A protein for 1 h and mixed with 1 × 10 6 CD8 + T cells at the ratio of 1:10. The cells were cultured with TNF- for 4 days at 37°C, 5% CO 2 . IL-2 (10 U/ml) was added at day 4 and the same amount of loaded DCs were added at day 7 and day 10. The cytotoxicity or CTL was measured at day 14 and day 21 as described (26) .
Micro
Preparation of target cells
Recombinant retrovirus (pGEZ-LMP2A) containing LMP2A gene was produced as described (26) . PBMCs were resuspended to a density of 1 × 10 6 cells/ml in 10% human AB serum and seeded into 24-well plate to let the cells attach. After 2 h, the nonattached cells were removed by gently rinsing the cells. Macrophages (M) were isolated by adherence and cultured in 37°C, 5% CO 2 for 24 h. On DAY 2, adherent cells were incubated with 1ml infectious recombinant or empty retroviral s/n supplemented with 1000 U/ml GM-CSF and 8 g/ml polybrene. This procedure was repeated on each of the following two days. On day 7 identification of LMP2A expression of infected macrophages and effector cells control (CTL in 1% FCS RPMI 1640) were set up. The plates were spinned at 1000 rpm for 10 min and then incubated at 37°C, 5% CO 2 for 12h. After incubation, the plates were spinned again at 1000 rpm for 20 min and 100 l supernatant were transferred into new 96-well plates. 100 l fresh-made reaction mixtures were added into each well, and then the plates were incubated at room temperature for 30 min, protected from light. The absorbance (A) of the samples were measured at 490/492 nm with a reference wavelength of 600 nm. The cytotoxicity rate is calculated according to the following equation: Cytotoxicity (%) = 100% × [(Triplicateeffector cells control -minimum cytotoxicity control) / (Maximum cytotoxicity control -minimum cytotoxicity control)]
Intracellular cytokines assay
The CTL induced by LMP2A loaded or unloaded DCs were stimulated in 6-well plate by autologous PBMCs for 3 times. After 3-week culture, the CTL were mixed with macrophages infected by retrovirus pGEZ-LMP2A and incubated at 37°C, in 5% CO 2 for 16 h. The cells were harvested into tube and incubated with 5 l of anti-CD3-FITC and 5 l anti-CD8-PE antibiodies (all from BD PharMingen) for 20 min at room temperature, protected from light. The cells with antibodies were fixed by incubating with 100 l of fixation for 20 min at room temperature. After the fixed cells were washed by 3 ml of PBS for 3 times. For the intracellular IFN-γ assay, CTL were treated with 100 μl permeabilization and 5 l of anti-IFN-γ-PE antibody (BD PharMingen) and incubated for 15 min at room temperature, protected from light. The cells were washed as before. All the measurements were performed on FACSCalibur. The gates for CD8 positive cells were set to calculate CD8 + , CD3
+ and IFN-γ + cells.
Statistical tests
Values are presented as mean ± SD. Results were analyzed by the Student t test for independent samples (2-tailed). Statistical significance for comparisons was assigned at p < 0.05.
Results
The infection status of EBV healthy carriers
To know the infection status of EBV healthy carriers, we measured the titers of anti-EBV antibodies (Figure1). The titers were shown in Figure 2A ), loaded DCs could stimulate proliferation of both CD4 + and CD8 + T cells comparing with unloaded DCs (Figure 2B ). The ability of stimulation increased with the increase of DC : T ratio. Even at 1 : 500 
EBV-LMP2 specific CD4
+ T cells secrete IFN-γ To determine whether the CD4 + T cells are functional, we measured IFN-γ and IL-10 secretion of CD4 + T cell stimulated by LMP2A loaded and unloaded. As shown in Figure 3 , when stimulated with LMP2A loaded DCs, autologous CD4 + T cells could secrete more IFN-γ into the supernatant than the control group (p = 0.031). That means those CD4 + T cells stimulated by LMP2A loaded DCs were functional and specific. We also tried to detect the IL-10 of each group. However using our ELISA method, we could not detect the IL-10 levels in the supernatants.
Determination of the expression level of transduced LMP2A in infected macrophages
To evaluate the generated CTL that recognize endogenously processed LMP2A antigen, macrophages infected with recombinant or empty retrovirus (pGEZ/LMP2A or pGEZ) were used as target cells. Transduced LMP2A will be quantified at the protein level and correlated to retroviral transduction efficiency, i.e. the proviral copy member. Flow cytometry of intact infected macrophages with rabbit anti-LMP2A antibody will be used to document surface expression of transduced LMP2A. For retroviral vector pGEZ containing GFP report gene, goat anti-rabbit conjugated with PE were then used as second Abs. GFP report gene expressed in unscreened infected macrophage cells under fluorescent microscope. As shown in Figure 4 , flow cytometry analysis results revealed 56.4% of the whole infected cells expressing LMP2A protein. Unlike peptide-loaded target cells, HLA genotyping of donors can not be considerated by using the infected autologous cells as targets.
Cytotoxic specificity of CTL induced by LMP2A loaded DC
To determine if the CTLs generated by LMP2A loaded DCs had cytotoxic activity and the cytotoxicity is specific, CTLs were tested against a panel of targets in cytotoxicity assays. LMP2A-specific CTLs were generated from healthy, HLA-A*0201-positive, EBV-seropositive healthy donors by stimulating CD8 + T cells with autologous LMP2A-expressed macrophages. At effector: target ratio from 20:1 to 5:1, CTLs generated by autologous LMP2A loaded DCs lysed autologous macrophages infected with retrovirus pGEZ/LMP2A ( Figure  4 , 63.8 ± 3.26%, 51.3 ± 1.19% and 37.9 ± 1.58%, respectively), where as autologous LCLs (34.1 ± 1.91%, 22.8 , macrophages infected with empty retrovirus (10.5 ± 0.98%, 9.3 ± 1.22 and 7.2 ± 0.65%, respectively) and MHC un-matched K562 cells (11.3 ± 1.26%, 6.8 ± 1.36 and 5.9 ± 0.51% respectively) were resistant to lyse. The cytotoxicity of the CTLs increased (79.7 ± 2.13%, 71.5 ± 3.04 and 53.7 ± 1.68% respectively) when stimulating time extended to 21 days whereas no increase found in groups using macrophagepGEZ, autologous or mismatched LCL, K562 as target cells ( Figure 5 , p < 0.05). 
Intracellular IFN-γ levels of EBV-LMP2A specific CD8 + T cells in EBV healthy carriers
Discussion
CD4
+ and CD8 + T cells play key roles in controlling the development of nasopharyngeal carcinoma and other EBV associated diseases (1, 6, 27, 28) . CD4 + T cells help B cells to produce antibodies and secrete cytokines to enhance anti-tumor immunity by stimulating NK cells, macrophages and CD8 + cytotoxic T cells as well. CD8 + T cells are the major effector of specific anti-tumor immunity. They recognize tumor antigens by TCR and kill tumor cells directly (29) (30) (31) (32) (33) . However, in EBV latency type II malignancy, LMP2 specific immune responses can be detected in 84% patients (24) . That implies malignancies developed despite the patients have a competent immunity. This phenomenon indicates an insufficiency of endogenous T cells to stop tumor growth. Thus, ex vivo expansion of the tumor-specific T cells is a potential strategy to circumvent the situation of immunosuppression. In our previous studies, we have shown using protein loaded DCs did not result in DCs dysfunction and were successfully induced functional HLA restrictive CTL in vitro (26) . Here, we further studied the subtypes of effector T cells and their immune responses towards targets cells. Our results indicate using LMP2A protein loaded DCs can elicit both CD4 + and CD8 + T cell mediated immunity towards LMP2A antigen in vitro.
Immature DCs have the capacity to capture and process exogenous antigens. Once maturing, DCs can cross-present processed antigens with MHC class I and MHC class II molecules (34) . DC vaccine has been considered as a novel therapeutic tool of cancer (35, 36) . EBV-LMP2A has many potential MHC class I and II epitopes, which make LMP2A an ideal antigen for eliciting both CD4 + and CD8 + T cell mediated anti-tumor immunity (22) (23) (24) (25) (26) 37) . In our study, we used purified EBV-LMP2A protein as an antigen to load DC directly. Using purified protein to load DCs has more advantages than other methods such as viral vector loading, peptides loading or liposome loading. First, full-length protein loading can keep all of the potential MHC class I and II epitopes for DCs processing and presenting. Second, protein loading appears much safer than using viral vector loading. Third, protein loading mimics physiological DCs capture and processing antigen in the body. It may maximize the capacity of DCs to present antigen and initiate immunity with minimized by side effects. Our study showed using LMP2A protein loading DCs can stimulate proliferation of both CD4 + and CD8 + T cells comparing with unloaded DCs. It suggests protein loading would not interfere with maturation and antigen presentation of DCs. And most importantly, DCs loaded with LMP2A can cross-present processed antigen via both MHC class I and II pathway, which is critical for anti-tumor immunity.
CTL are major effectors in anti-tumor immunity. Two mechanisms are involved in the cytotoxicity of CTL. One is via directly kills tumor cells through direct lysis or inducing apoptosis of tumor cells. Whether a tumor immunotherapy is successful depends mostly on its efficacy and efficiency to elicit tumor specific CTL (16, (25) (26) (27) (28) 38) . In our study, we found LMP2A protein-loaded DCs can induce CTL responses against LMP2A expressing target cells. The subgroups of the CTL contain CTL which lyses target cells directly and also participate anti-tumor immune response by secreting IFN-γ and TNF-. The latter has been proved to be able to destroy tumor cells indirectly.
TH1 type CD4 + T cells secret cytokines to activate other components of immune system. It is believed that a shift from TH2 to TH1 type immune response is critical for immune system to fight against tumor cells. This shift is determined by the cytokine profile of the antigen presenting cells (APCs) (39) (40) (41) . DCs can secrete IL-12, a TH1 type cytokine, to induce Th0 T cells differentiate into TH1 type T cells when they present tumor antigen (34, 42) . In this study, we found CD4 + T cells induced by LMP2A-loaded DCs produced a large amount of IFN-γ, but no IL-10, which indicates they are Th1 type. These CD4 + T cells can enhance anti-tumor immunity by activating NK cells, macrophages and CTL by producing IFN-γ and other cytokines.
In summary, this study showed that purified LMP2A protein loaded DCs efficiently stimulated both CD8 + and CD4 + T cells which have specific immune-function against EBV-LMP2A expressing target cells in vitro, therefore suggesting that LMP2A protein loaded DCs are promising polyvalent vaccine for immunotherapy targeting LMP2A-expressing EBV associated malignancy. Future studies will be conducted in the tumor models we have established (43), and the immune response types will be monitored carefully to evaluate the efficacy of the DC vaccine. 
